PDCD1 and neoplasm: Pre-clinical studies further elucidated that neutralizing PCSK9 during anti-PD-1 therapy could generate a synergistic anti-tumor effect for colorectal cancer, potentially by promoting CD8+T cell infiltration and inflammatory cytokine release, as well as inhibiting the recruitment of Treg cells [15].